Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-15 |
2024-03 |
-0.66 |
-0.53 |
0.13 |
19.70% |
2024-02-14 |
2023-12 |
-0.43 |
-0.56 |
-0.13 |
-30.23% |
2023-11-14 |
2023-09 |
-0.75 |
-0.48 |
0.27 |
36.00% |
2023-09-28 |
2023-06 |
-0.59 |
-0.91 |
-0.32 |
-54.24% |
2023-05-16 |
2023-03 |
-0.59 |
-0.63 |
-0.04 |
-6.78% |
2023-02-14 |
2022-12 |
-0.77 |
-0.66 |
0.11 |
14.29% |
Date |
Firm |
Action |
From |
To |
2023-08-09 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-07 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-06 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-29 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-08 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-03-12 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-04-10 |
DE VEER ROBERT K JR |
Director |
40.85K |
Purchase |
2023-12-03 |
DUNTON ALAN WILLIAM |
Director |
45.07K |
Sale |
2015-12-07 |
HOROVITZ ZOLA P |
Director |
250.67K |
Stock Award(Grant) |
2023-06-19 |
HULL JOSEPH STANLEY |
Director |
47.59K |
Stock Award(Grant) |
2023-06-19 |
MANNING ANTHONY M |
Director |
36.69K |
Stock Award(Grant) |
2023-06-19 |
MORRIS ARLENE M |
Director |
45.09K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
382.55K |
803.36K |
3.20% |
2023-06-29 |
Blackrock Inc. |
246.79K |
518.26K |
2.07% |
2023-06-29 |
Geode Capital Management, LLC |
66.28K |
139.19K |
0.55% |
2023-06-29 |
State Street Corporation |
30.30K |
63.62K |
0.25% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
26.12K |
54.86K |
0.22% |
2023-06-29 |
Montis Financial, LLC |
20.96K |
44.02K |
0.18% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
246.70K |
518.08K |
2.07% |
2023-08-30 |
iShares Core S&P Total U.S. Stock Market ETF |
127.72K |
263.11K |
1.07% |
2023-06-29 |
Vanguard Extended Market Index Fund |
115.67K |
242.90K |
0.97% |
2023-05-30 |
Fidelity Extended Market Index Fund |
40.49K |
99.21K |
0.34% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
24.80K |
52.08K |
0.21% |
2023-05-30 |
Fidelity Total Market Index Fund |
10.93K |
26.78K |
0.09% |
Split |
Date |
1 : 25 |
2022-08-31 |
0.1 : 1 |
2010-09-27 |